Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Календарь
Скринер
Новости
О нас

CLPT - ClearPoint Neuro, Inc. Последние новости | Finranks

Home

/

CLPT

C

ClearPoint Neuro, Inc. (CLPT)

NCM – Цена в реальном времени. Валюта: USD

14.77

-0.13 (-0.87%)

Рынок открыт: Aug 12, 2026, 11:36 AM EDT

14.60

-0.30 (-2.01%)

Предыдущая сессия: Aug 11, 2026, 7:34 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case

ClearPoint Neuro: Regulatory Momentum Strengthens The Long-Term Investment Case

ClearPoint Neuro's second quarter results were poor across the board, with drug delivery disposables an area of particular weakness. Delays in the ramping of preclinical services at ClearPoint's new facility have also contributed to reduced expectations for 2026. There is now regulatory clarity, though, meaning a revenue inflection as AMT-130 is commercialized is now highly likely in 2027/2028.

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) Q2 2026 Earnings Call Transcript

ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say

ClearPoint Neuro (CLPT) Reports Q2 Earnings: What Key Metrics Have to Say

The headline numbers for ClearPoint Neuro (CLPT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) Reports Q2 Loss, Misses Revenue Estimates

ClearPoint Neuro, Inc. (CLPT) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.21 per share a year ago.

ClearPoint Neuro Q2 Earnings Call Highlights

ClearPoint Neuro Q2 Earnings Call Highlights

ClearPoint Neuro NASDAQ: CLPT reported second-quarter 2026 revenue growth while outlining a shift in investment priorities toward clinical capacity, preclinical laboratory services and technologies intended to support commercial-scale neuro drug delivery.

ClearPoint Neuro Reports Second Quarter 2026 Results

ClearPoint Neuro Reports Second Quarter 2026 Results

Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Highlights Reported second quarter revenue of $10.9 million, representing 18% overall growth, including the recently acquired IRRAflow Portfolio; Biologics and Drug Delivery Revenue declined 15% in the quarter, primarily due to a decrease in products shipped to biopharma customers supporting new trial initiations compared to the second quarter a year ago.

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulated its partner Aspen Neuroscience, Inc. on receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for sasineprocel (ANPD001), Aspen's investigational autologous dopaminergic neuron cell replacement therapy for Parkinson's disease.

Видео

No Data

There is no data to display

Пресс-релизы

ClearPoint Neuro Reports Second Quarter 2026 Results

ClearPoint Neuro Reports Second Quarter 2026 Results

Positive BioPharma Partner Regulatory Progress and Early Success in Focused Ultrasound Technology Platform Expansion SOLANA BEACH, CA / ACCESS Newswire / August 3, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today announced financial results for its second quarter ended June 30, 2026. Second Quarter 2026 Highlights Reported second quarter revenue of $10.9 million, representing 18% overall growth, including the recently acquired IRRAflow Portfolio; Biologics and Drug Delivery Revenue declined 15% in the quarter, primarily due to a decrease in products shipped to biopharma customers supporting new trial initiations compared to the second quarter a year ago.

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel

RMAT Designation Supports an Expedited FDA Development and Review Pathway for Aspen's Investigational Autologous Cell Replacement Therapy for Parkinson's Disease. SOLANA BEACH, CA / ACCESS Newswire / July 31, 2026 / ClearPoint Neuro, Inc. (Nasdaq:CLPT) (the "Company"), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulated its partner Aspen Neuroscience, Inc. on receiving Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. Food and Drug Administration (FDA) for sasineprocel (ANPD001), Aspen's investigational autologous dopaminergic neuron cell replacement therapy for Parkinson's disease.